---
document_datetime: 2025-12-02 04:53:57
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-neuraxpharm.html
document_name: dimethyl-fumarate-neuraxpharm.html
version: success
processing_time: 0.1040189
conversion_datetime: 2025-12-26 11:58:20.955919
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Dimethyl fumarate Neuraxpharm

[RSS](/en/individual-human-medicine.xml/240136)

##### Authorised

This medicine is authorised for use in the European Union

dimethyl fumarate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Dimethyl fumarate Neuraxpharm](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Dimethyl fumarate Neuraxpharm is a medicine used to treat multiple sclerosis (MS), a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. It is used in adults and adolescents from 13 years of age with a type of MS known as relapsing-remitting MS, where the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).

Dimethyl fumarate Neuraxpharm contains the active substance dimethyl fumarate and is a 'generic medicine'. This means that Dimethyl fumarate Neuraxpharm contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Dimethyl fumarate Neuraxpharm is Tecfidera. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Dimethyl fumarate Neuraxpharm used?

Dimethyl fumarate Neuraxpharm can only be obtained with a prescription and treatment should be started under the supervision of a doctor experienced in treating MS.

Dimethyl fumarate Neuraxpharm is available as capsules to be taken by mouth, twice a day with food. During the first week of treatment a lower dose is taken, which is then increased from the second week. The dose may be reduced temporarily in patients experiencing side effects of flushing and gastrointestinal (stomach and gut) problems.

For more information about using Dimethyl fumarate Neuraxpharm, see the package leaflet or contact your doctor or pharmacist.

## How does Dimethyl fumarate Neuraxpharm work?

In MS, the immune system (the body's natural defences) attacks and damages the protective insulation around the nerves and the nerves themselves in the brain, spinal cord and optic nerve of the eye. The active substance in this medicine, dimethyl fumarate, is thought to work by activating a protein called 'Nrf2' that regulates certain genes that produce 'antioxidants' involved in protecting cells from damage.

Dimethyl fumarate has been shown to reduce inflammation and modulate the activity of the immune system.

## How has Dimethyl fumarate Neuraxpharm been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Tecfidera, and do not need to be repeated for Dimethyl fumarate Neuraxpharm.

As for every medicine, the company provided studies on the quality of Dimethyl fumarate Neuraxpharm. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Dimethyl fumarate Neuraxpharm?

Because Dimethyl fumarate Neuraxpharm is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Dimethyl fumarate Neuraxpharm authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Dimethyl fumarate Neuraxpharm has been shown to have comparable quality and to be bioequivalent to Tecfidera. Therefore, the Agency's view was that, as for Tecfidera, the benefits of Dimethyl fumarate Neuraxpharm outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Dimethyl fumarate Neuraxpharm?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dimethyl fumarate Neuraxpharm have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Dimethyl fumarate Neuraxpharm are continuously monitored. Suspected side effects reported with Dimethyl fumarate Neuraxpharm are carefully evaluated and any necessary action taken to protect patients.

## Other information about Dimethyl fumarate Neuraxpharm

Dimethyl fumarate Neuraxpharm received a marketing authorisation valid throughout the EU on 22 April 2024.

Dimethyl fumarate Neuraxpharm : EPAR - Medicine overview

Reference Number: EMA/177991/2024

English (EN) (145.32 KB - PDF)

**First published:** 11/07/2024

[View](/en/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_en.pdf-0)

[Other languages (22)](#file-language-dropdown-458)

български (BG) (168.84 KB - PDF)

**First published:**

11/07/2024

[View](/bg/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_bg.pdf-0)

español (ES) (146.43 KB - PDF)

**First published:**

11/07/2024

[View](/es/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_es.pdf-0)

čeština (CS) (165.14 KB - PDF)

**First published:**

11/07/2024

[View](/cs/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_cs.pdf-0)

dansk (DA) (144.8 KB - PDF)

**First published:**

11/07/2024

[View](/da/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_da.pdf-0)

Deutsch (DE) (148.56 KB - PDF)

**First published:**

11/07/2024

[View](/de/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_de.pdf-0)

eesti keel (ET) (133.68 KB - PDF)

**First published:**

11/07/2024

[View](/et/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_et.pdf-0)

ελληνικά (EL) (170.78 KB - PDF)

**First published:**

11/07/2024

[View](/el/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_el.pdf-0)

français (FR) (147.85 KB - PDF)

**First published:**

11/07/2024

[View](/fr/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_fr.pdf-0)

hrvatski (HR) (164.37 KB - PDF)

**First published:**

11/07/2024

[View](/hr/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_hr.pdf-0)

italiano (IT) (144.73 KB - PDF)

**First published:**

11/07/2024

[View](/it/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_it.pdf-0)

latviešu valoda (LV) (184.26 KB - PDF)

**First published:**

11/07/2024

[View](/lv/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_lv.pdf-0)

lietuvių kalba (LT) (165.69 KB - PDF)

**First published:**

11/07/2024

[View](/lt/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_lt.pdf-0)

magyar (HU) (166.3 KB - PDF)

**First published:**

11/07/2024

[View](/hu/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_hu.pdf-0)

Malti (MT) (168.19 KB - PDF)

**First published:**

11/07/2024

[View](/mt/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_mt.pdf-0)

Nederlands (NL) (146.11 KB - PDF)

**First published:**

11/07/2024

[View](/nl/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_nl.pdf-0)

polski (PL) (169.15 KB - PDF)

**First published:**

11/07/2024

[View](/pl/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_pl.pdf-0)

português (PT) (145.54 KB - PDF)

**First published:**

11/07/2024

[View](/pt/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_pt.pdf-0)

română (RO) (163.81 KB - PDF)

**First published:**

11/07/2024

[View](/ro/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_ro.pdf-0)

slovenčina (SK) (165.24 KB - PDF)

**First published:**

11/07/2024

[View](/sk/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_sk.pdf-0)

slovenščina (SL) (162.73 KB - PDF)

**First published:**

11/07/2024

[View](/sl/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_sl.pdf-0)

Suomi (FI) (143.4 KB - PDF)

**First published:**

11/07/2024

[View](/fi/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_fi.pdf-0)

svenska (SV) (145.21 KB - PDF)

**First published:**

11/07/2024

[View](/sv/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_sv.pdf-0)

Dimethyl fumarate Neuraxpharm : EPAR - Risk-management-plan

English (EN) (1.5 MB - PDF)

**First published:** 11/07/2024

[View](/en/documents/rmp-summary/dimethyl-fumarate-neuraxpharm-epar-risk-management-plan_en.pdf)

## Product information

Dimethyl fumarate Neuraxpharm : EPAR - Product information

English (EN) (395.91 KB - PDF)

**First published:** 11/07/2024

**Last updated:** 13/02/2025

[View](/en/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-729)

български (BG) (536.66 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/bg/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_bg.pdf)

español (ES) (363.13 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/es/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_es.pdf)

čeština (CS) (725.02 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/cs/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_cs.pdf)

dansk (DA) (367.43 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/da/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_da.pdf)

Deutsch (DE) (407.17 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/de/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_de.pdf)

eesti keel (ET) (381.03 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/et/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_et.pdf)

ελληνικά (EL) (495.91 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/el/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_el.pdf)

français (FR) (422.86 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/fr/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_fr.pdf)

hrvatski (HR) (446.9 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/hr/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_hr.pdf)

íslenska (IS) (370.99 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/is/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_is.pdf)

italiano (IT) (370.8 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/it/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_it.pdf)

latviešu valoda (LV) (461.24 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/lv/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_lv.pdf)

lietuvių kalba (LT) (470.59 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/lt/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_lt.pdf)

magyar (HU) (748.19 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/hu/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_hu.pdf)

Malti (MT) (487.38 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/mt/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_mt.pdf)

Nederlands (NL) (583.71 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/nl/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_nl.pdf)

norsk (NO) (382.64 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/no/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_no.pdf)

português (PT) (368.2 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/pt/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_pt.pdf)

română (RO) (507.17 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/ro/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_ro.pdf)

slovenčina (SK) (669.24 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/sk/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_sk.pdf)

slovenščina (SL) (471.9 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/sl/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_sl.pdf)

Suomi (FI) (367.36 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/fi/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_fi.pdf)

svenska (SV) (414.71 KB - PDF)

**First published:**

11/07/2024

**Last updated:**

13/02/2025

[View](/sv/documents/product-information/dimethyl-fumarate-neuraxpharm-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000246862 12/02/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Dimethyl fumarate Neuraxpharm : EPAR - All authorised presentations

English (EN) (23.7 KB - PDF)

**First published:** 11/07/2024

[View](/en/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_en.pdf-0)

[Other languages (24)](#file-language-dropdown-888)

български (BG) (47.26 KB - PDF)

**First published:**

11/07/2024

[View](/bg/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_bg.pdf-0)

español (ES) (27.07 KB - PDF)

**First published:**

11/07/2024

[View](/es/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_es.pdf-0)

čeština (CS) (31.67 KB - PDF)

**First published:**

11/07/2024

[View](/cs/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_cs.pdf-0)

dansk (DA) (21.17 KB - PDF)

**First published:**

11/07/2024

[View](/da/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_da.pdf-0)

Deutsch (DE) (21.21 KB - PDF)

**First published:**

11/07/2024

[View](/de/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_de.pdf-0)

eesti keel (ET) (21.35 KB - PDF)

**First published:**

11/07/2024

[View](/et/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_et.pdf-0)

ελληνικά (EL) (46.27 KB - PDF)

**First published:**

11/07/2024

[View](/el/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_el.pdf-0)

français (FR) (47.29 KB - PDF)

**First published:**

11/07/2024

[View](/fr/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_fr.pdf-0)

hrvatski (HR) (40.76 KB - PDF)

**First published:**

11/07/2024

[View](/hr/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_hr.pdf-0)

íslenska (IS) (21.41 KB - PDF)

**First published:**

11/07/2024

[View](/is/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_is.pdf-0)

italiano (IT) (21.7 KB - PDF)

**First published:**

11/07/2024

[View](/it/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_it.pdf-0)

latviešu valoda (LV) (46.14 KB - PDF)

**First published:**

11/07/2024

[View](/lv/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_lv.pdf-0)

lietuvių kalba (LT) (43.49 KB - PDF)

**First published:**

11/07/2024

[View](/lt/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_lt.pdf-0)

magyar (HU) (31.61 KB - PDF)

**First published:**

11/07/2024

[View](/hu/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_hu.pdf-0)

Malti (MT) (42.57 KB - PDF)

**First published:**

11/07/2024

[View](/mt/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_mt.pdf-0)

Nederlands (NL) (31.26 KB - PDF)

**First published:**

11/07/2024

[View](/nl/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_nl.pdf-0)

norsk (NO) (21.39 KB - PDF)

**First published:**

11/07/2024

[View](/no/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_no.pdf-0)

polski (PL) (33.32 KB - PDF)

**First published:**

11/07/2024

[View](/pl/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_pl.pdf-0)

português (PT) (21.25 KB - PDF)

**First published:**

11/07/2024

[View](/pt/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_pt.pdf-0)

română (RO) (42.87 KB - PDF)

**First published:**

11/07/2024

[View](/ro/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_ro.pdf-0)

slovenčina (SK) (31.58 KB - PDF)

**First published:**

11/07/2024

[View](/sk/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_sk.pdf-0)

slovenščina (SL) (29.77 KB - PDF)

**First published:**

11/07/2024

[View](/sl/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_sl.pdf-0)

Suomi (FI) (21.59 KB - PDF)

**First published:**

11/07/2024

[View](/fi/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_fi.pdf-0)

svenska (SV) (21.31 KB - PDF)

**First published:**

11/07/2024

[View](/sv/documents/all-authorised-presentations/dimethyl-fumarate-neuraxpharm-epar-all-authorised-presentations_sv.pdf-0)

## Product details

Name of medicine Dimethyl fumarate Neuraxpharm Active substance dimethyl fumarate International non-proprietary name (INN) or common name dimethyl fumarate Therapeutic area (MeSH) Multiple Sclerosis Anatomical therapeutic chemical (ATC) code L04AX07

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Dimethyl fumarate Neuraxpharm is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).

## Authorisation details

EMA product number EMEA/H/C/006500

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Neuraxpharm Pharmaceuticals S.L.

Avinguda De Barcelona 69 Poligono Industrialde La Fuensanta 08970 Sant Joan Despi SPAIN

Opinion adopted 21/03/2024 Marketing authorisation issued 22/04/2024 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Dimethyl fumarate Neuraxpharm : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (145.27 KB - PDF)

**First published:** 13/02/2025

[View](/en/documents/procedural-steps-after/dimethyl-fumarate-neuraxpharm-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Dimethyl fumarate Neuraxpharm : EPAR - Public assessment report

Adopted

Reference Number: EMA/321710/2024

English (EN) (836.84 KB - PDF)

**First published:** 11/07/2024

[View](/en/documents/assessment-report/dimethyl-fumarate-neuraxpharm-epar-public-assessment-report_en.pdf-0)

CHMP summary of positive opinion for Dimethyl fumarate Neuraxpharm

Adopted

Reference Number: EMA/CHMP/104444/2024

English (EN) (130.76 KB - PDF)

**First published:** 22/03/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-dimethyl-fumarate-neuraxpharm_en.pdf-0)

#### News on Dimethyl fumarate Neuraxpharm

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024) 22/03/2024

**This page was last updated on** 13/02/2025

## Share this page

[Back to top](#main-content)